Updates to the Management of HR-Positive, HER2-Negative Breast Cancer ...
May 31, 2024 · Metastatic hormone receptor–positive, HER2-negative breast cancer treatment is increasingly individualized as more of the tumor landscape is described and targeted therapies …
Neratinib Plus Capecitabine for the Treatment of Her2-Negative ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary …
New Drug Combination Improves Survival for ER+, HER2- Breast Cancer
May 31, 2025 · Inavolisib Triplet Therapy Clinical Trial Results Now a phase 3 clinical trial has shown that a new three-drug combination enabled ER-positive, HER2-negative breast cancer …
ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer ...
Aug 24, 2022 · An ASCO Expert Panel has updated the treatment guidelines on chemotherapy and targeted therapy for patients with HER2-negative metastatic breast cancer to include …
Nov 26, 2025 · The phase 3, randomized, open-label, international PATINA trial evaluated the efficacy and safety of the addition of the CDK4/6 inhibitor, palbociclib, to standard first-line …
A Phase I Trial of Alpelisib Combined With Capecitabine in
Abstract Background: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human …
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative …
May 13, 2025 · In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden …
Treatment for HER2-Negative Advanced Breast Cancer - WebMD
Mar 1, 2025 · If your breast cancer is HER2-negative and advanced, what are your treatment options? Learn how hormonal therapies, chemotherapy, targeted therapies, and …
Overall survival with sacituzumab govitecan in hormone receptor ...
Oct 21, 2023 · Background Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with …
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast …
Feb 14, 2024 · A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators …